These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 11904965)

  • 21. Monitoring immune responses after glioma vaccine immunotherapy.
    Jian B; Yang I; Parsa AT
    Neurosurg Clin N Am; 2010 Jan; 21(1):195-9. PubMed ID: 19944978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells].
    Nitta T; Ishizawa A; Ito M; Sato K; Yagita H; Kumura K
    No Shinkei Geka; 1990 Nov; 18(11):1001-6. PubMed ID: 2247192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive immunotherapy of CNS malignancies.
    Plautz GE; Shu S
    Cancer Chemother Biol Response Modif; 2001; 19():327-38. PubMed ID: 11686021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Inhibition of angiogenesis and growth of malignant gliomas in the athymic nude rat model: immunotherapy against "basic fibroblast growth factor"].
    Nemati MN; Stan AC; Pütz KM; Pietsch T; Walter GF; Dietz H
    Zentralbl Neurochir; 1996; 57(1):12-9. PubMed ID: 8900894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
    Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
    Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor immunology: a neurosurgical perspective. II. The immunology of glial neoplasms.
    Apuzzo ML
    Bull Los Angeles Neurol Soc; 1976 Oct; 41(4):176-83. PubMed ID: 74264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
    Lee Y; Bullard DE; Humphrey PA; Colapinto EV; Friedman HS; Zalutsky MR; Coleman RE; Bigner DD
    Cancer Res; 1988 May; 48(10):2904-10. PubMed ID: 2452014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogene therapy as a treatment for malignant brain tumors in young mice.
    Glick RP; Lichtor T; Lin H; Tarlock K; Cohen EP
    J Neurosurg; 2006 Jul; 105(1 Suppl):65-70. PubMed ID: 16871873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
    Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mahaley Clinical Research Award: chemosensitization of glioma through dendritic cell vaccination.
    Yu JS; Luptrawan A; Black KL; Liu G
    Clin Neurosurg; 2006; 53():345-51. PubMed ID: 17380773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment modalities for malignant gliomas with reference to their pathophysiology].
    Kobayashi S; Takakura K
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):11-7. PubMed ID: 3942392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cell-based glioma immunotherapy (review).
    Yamanaka R; Yajima N; Abe T; Tsuchiya N; Homma J; Narita M; Takahashi M; Tanaka R
    Int J Oncol; 2003 Jul; 23(1):5-15. PubMed ID: 12792771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Peptide vaccination therapy for malignant glioma].
    Yamanaka R; Itoh K
    Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pritumumab, the first therapeutic antibody for glioma patients.
    Babic I; Nurmemmedov E; Yenugonda VM; Juarez T; Nomura N; Pingle SC; Glassy MC; Kesari S
    Hum Antibodies; 2018 Feb; 26(2):95-101. PubMed ID: 29036806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for malignant gliomas.
    Bloch O
    Cancer Treat Res; 2015; 163():143-58. PubMed ID: 25468230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody.
    Aotsuka Y; Hagiwara H
    Eur J Cancer Clin Oncol; 1988 May; 24(5):829-38. PubMed ID: 3049115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
    Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
    Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy and adverse effects of beta-interferon in the treatment of malignant glioma].
    Oda Y; Konishi T; Suzui H; Kamijo Y; Kang Y; Okumura T; Kaneko T; Kikuchi H
    Nihon Gan Chiryo Gakkai Shi; 1989 Oct; 24(10):2411-7. PubMed ID: 2614179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.